MEPs call for better incentives to research childhood cancers

Written by Martin Banks on 23 December 2016 in News
News

Centre-right MEPs have urged the EU to improve the current legislation to encourage research into child cancers.

Françoise Grossetête

Françoise Grossetête | Photo credit: European Parliament audiovisual


A resolution says that research in the field of paediatrics, especially on childhood cancer, remains “far too sparse.”

In the 10 years since the entry-into-force of the 2006 paediatric medicines regulations, only two anti-cancer drugs have come onto the market.

“This situation is no longer sustainable and we ask the European Commission to improve the current legislation", said French deputy Françoise Grossetête, from the EPP group, which has drafted the resolution on the subject.


RELATED CONTENT


Every year in Europe, 6000 children die of cancer and improving research in paediatrics could save lives, she says.

The European Commission is due to publish a report on the implementation of the 2006 paediatric medicines regulations in 2017.

But Grossetête wants it to act as soon as possible, saying, “I have seen too many parents who have lost their children for lack of treatments, even though they are suffering from diseases that can be treated in adults."

The resolution promotes various concrete proposals to the Commission, including the review of the many exemptions that often prevent laboratories from their obligations to carry out 'paediatric investigation plans'.

Grossetête said, "The implementation of these plans, which was made mandatory by the 2006 regulations, is not respected because of rigid procedures, the narrowness of the market and the complexity of science.”

To reverse this trend, MEPs are also calling on the Commission to put in place a “genuine incentive system” for research that “punishes industrials who do not play ball.”

This system, said Grossetête, should also make it possible to encourage laboratories, via tax incentives or extensions of patent protection for example, to develop only paediatric indications that are not necessarily 'modelled' on adult products.

 

About the author

Martin Banks is a senior reporter for the Parliament Magazine

Interested in this content?

Sign up to our free daily email bulletins.

 

Share this page

Tags

Categories

Related Articles

MEP Awards 2017 MEP awards 2017: A few words from the winners
23 March 2017

Maltese deputy Roberta Metsola hosted the Parliament Magazine's annual MEP awards ceremony recognising MEPs for their outstanding work over the last year.

Sustainable energy EU energy union: No 'one-size-fits-all' - but technology can help
22 March 2017

Completing the energy union means ensuring a well-functioning internal energy market that empowers consumers, say MEPs.

Marie-Christine Vergiat Data protection rules must apply to all
20 March 2017

The digital revolution presents many opportunities, but embracing it must not come at the expense of fundamental rights, says Marie-Christine Vergiat.

Related Partner Content

Animal health PM+: Managing the environmental impact of animal pharmaceuticals
11 June 2015

What is the best way to address societal and political concerns about the impact of pharmaceuticals on the environment? IFAH-Europe's...

Field PM+: GMO authorisation needs legal certainty
26 October 2015

Ahead of the European Parliament’s vote on the use of GMOs, Nathalie Moll calls for a shift to a more coherent and science-based approach to EU policymaking.

IFAH-Europe, AMR, antimicrobial resistance, animals, PM+: Monitoring and transparency key to tackling animal antibiotic resistance
20 February 2015

There is a weak correlation between animal consumption of antibiotics and human resistance, argues Rick Clayton.